Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 1/2019

01-05-2019 | Migraine | Focus on

Catastrophizing attitude changes after onabotulinumtoxin A treatment in chronic migraine

Authors: Licia Grazzi, Eleonora Grignani, Emanuela Sansone, Alberto Raggi, Domenico D’Amico, Frank Andrasik

Published in: Neurological Sciences | Special Issue 1/2019

Login to get access

Excerpt

Chronic migraine is a difficult condition to treat and few evidence-based treatments have demonstrated their efficacy. Based on the results from a phase III clinical trial program (PREEMPT), onabotulinumtoxin A (OBT-A) has been approved for symptom relief in patients with chronic migraine who have failed, or do not tolerate, oral prophylactic treatments. Even if the results from the clinical studies are encouraging, several aspects of OBT-A use in clinical practice are still controversial and they are the argument of the discussion. Chronic migraine is a problematic condition and always associated with high levels of disability, lessened quality of life and high catastrophizing attitude [1, 2]. …
Literature
1.
Holroyd K, Drew B et al (2007) Impaired functioning and quality of life in severe migraine: the role of catastrophizing and associated symptoms. Cephalalgia 27(10):1156–1165CrossRefPubMedPubMedCentral
2.
Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC (2015) Prophylactic onabotulinumtoxin A in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression and anxiety. Int J Gen Med 9:79–86CrossRef
3.
Metadata
Title
Catastrophizing attitude changes after onabotulinumtoxin A treatment in chronic migraine
Authors
Licia Grazzi
Eleonora Grignani
Emanuela Sansone
Alberto Raggi
Domenico D’Amico
Frank Andrasik
Publication date
01-05-2019
Publisher
Springer International Publishing
Keywords
Migraine
Headache
Published in
Neurological Sciences / Issue Special Issue 1/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-019-03816-4

Other articles of this Special Issue 1/2019

Neurological Sciences 1/2019 Go to the issue

Focus on

Cerebral venous outflow in migraine

Review Article

Anti-CGRP in cluster headache therapy

Review Article

Headache attributed to IIH: clinical evolution in IHS criteria through the years

Focus on

Binaural stimulation in migraine: preliminary results from a 3-month evening treatment

Review Article

Dural sinus collapsibility, idiopathic intracranial hypertension, and the pathogenesis of chronic migraine

Focus on

Headache and kidney transplantation: an intriguing relationship